NuSomnea

Curated by Signal

Urinary biomarker for the diagnosis & management of OSA

Overview

NuSomnea develops tests for the diagnosis and management of Obstructive Sleep Apnea (OSA). NuSomnea aims to replace overnight sleep tests with an alternative daytime test. The NuSomnea test involves the assay of multiple urinary peptide biomarkers. The company claims to have secured intellectual property rights for the assay. The urine biomarker test currently focus on the pediatric OSA population and aims to develop a similar test for adults.

Key facts

Founded: 2012
Headquarters: Annapolis, United States
Stage: Sign up to view
Industry: Life Sciences Technology

More on Vanberra Signal

Members only

Business overviewCore metrics and financials PeopleLeadership and key people Similar companiesPeers and competitors Deep AnalysisAI-generated strategic report

Competitors & similar companies

More Life Sciences Technology companies

BINTO
Personalized supplements for women
Life Sciences TechnologyPhiladelphia, United States
Granata Bio
Developer of therapeutics for women's health and infertility
Life Sciences TechnologyDuxbury, United States
Happy V
Provider of nutritional products for women's health
Life Sciences TechnologyMiramar, United States

About NuSomnea

What does NuSomnea do?

NuSomnea develops tests for the diagnosis and management of Obstructive Sleep Apnea (OSA).

Where is NuSomnea headquartered?

NuSomnea is headquartered in Annapolis, United States.

When was NuSomnea founded?

NuSomnea was founded in 2012.

Which sector is NuSomnea in?

NuSomnea operates in Life Sciences Technology.

Who are NuSomnea's competitors?

Companies similar to NuSomnea include BINTO, Granata Bio, and Happy V.